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Abstract
Bioluminescence resonance energy transfer (BRET) is a distance dependent, non-radiative
energy transfer, which uses a bioluminescent protein to excite an acceptor through resonance
energy transfer. In this thesis, BRET technology is incorporated into a sensor comprised of a
recombinant protein and quantum dots. The recombinant protein, which includes the
bioluminescent protein, Renilla luciferase (Rluc), is used as the donor molecule and
cadmium tellurium quantum dots as the acceptor molecules. Separating the donor-acceptor
pair is a recombinant protein, glucose binding protein, which changes conformation upon
binding glucose and brings the pair closer together, thus allowing BRET to occur.
Optimization of the BRET sensor was investigated by evaluating different ratios of the donor
and acceptor, changes in the bioconjugation process, and different glucose concentrations.
The intensity of bioluminescence is a function of the ratio between the quantum dots to
protein, which ranges from 1:6 to 0.0156:1, EDC ratio to quantum dots, conjugation time,
and concentration of glucose ranging from 2 μM to 0.1 M. In addition, the performance of
the sensor on a solid substrate was evaluated. This sensor promises to offer an alternative to
traditional blood glucose sensing.

Keywords
Bioluminescence resonance energy transfer, BRET, Renilla luciferase, Quantum dots,
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Summary for Lay Audience
Type 1 diabetes is a disease characterized by loss of blood glucose control due to
autoimmune destruction of pancreatic beta islet cells. Modern treatment requires the use of a
blood glucose meter, often requiring the pricking of the finger. Constant pricking is a
detriment to the quality of life to these patients and may lead to decreases in patient
adherence. The goal of this project is to develop a non-invasive alternative to measuring
blood glucose by utilizing tears. A newly designed sensor using a technology known as
bioluminescence resonance energy transfer (BRET) has been developed with the hopes that it
may replace traditional glucose sensing methods. BRET occurs when a light emitting protein
transfers light energy to another light emitting protein. The second protein will then emit its
own light, which can then be measured. The newly designed sensor uses quantum dots in the
place of a second protein due to unique properties that make them suitable for glucose
sensing. The sensor components are separated by a glucose binding protein, which changes
conformation upon binding glucose. Therefore, the amount of light emitted by the quantum
dot will correspond to whether glucose has bound the sensor. Testing of the sensor revealed
that a 0.3125:1 ratio of the protein to quantum dots to be ideal. In addition, the sensor could
detect variations of glucose levels ranging between 2 µM to 0.1 M, which is sufficient to
detect levels of glucose in both tear samples and blood samples. The sensor was also tested
while deposited on a solid substrate. The results indicate the sensor may be promising as an
alternative to traditional blood glucose sensing.
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Chapter 1

1

Introduction

1.1 Glucose sensors in diabetes
Type 1 diabetes is a metabolic disorder characterized by loss of blood glucose control due
to the autoimmune destruction of insulin-producing beta islet cells. This loss of blood
glucose control can lead to a variety of complications due to hyperglycemia. Many diabetic
patients are at increased risk of cardiovascular and neurovascular disease. Careful and
accurate monitoring of blood glucose is essential for patients with type 1 diabetes in order
to reduce the risk of hypoglycemia and other related complications [1]. Traditional blood
glucose monitoring techniques utilize a blood glucose meter. These meters require the
pricking of the patient’s finger to obtain a small blood sample [2]. This method is a
detriment to the quality of life to these patients, as constant pricking throughout the day is
often painful and inconvenient. Constant pricking may decrease patient adherence to
treatment, therefore current efforts have focused on the development of a non-invasive
means of glucose monitoring [3].
Recent works have investigated the measurement of changes in blood glucose as they
related to changes in other related chemical and physical properties of the body. For
example, changes in other body fluids such as urine [4,5], sweat [6–8], and tears [9,10]
have provided new avenues to assess changes in blood glucose in a non-invasive manner.
Due to significantly lower values of glucose in related body fluids, methods with increased
sensitivity need to be developed in order to accurately measure glucose levels.
The most popular traditional glucose biosensors are based on glucose interactions with
enzymes such as glucose oxidase (GOx) [11]. Also known as enzymatic amperometric
sensors, these sensors use immobilized GOx to oxidize glucose which forms hydrogen
peroxide [12]. The hydrogen peroxide is oxidized at a catalytic, platinum anode where the
electrode can recognize the number of electron transfers. The electron flow is proportional
to the number of glucose molecules present in the medium [13].
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Glucose biosensors are designed to be used for point-of-care testing and are easily operated
by outpatients [14]. However, the American Diabetes Association recommends that the
accuracy of such biosensors should be less than 5% of the measured value, which many
devices fail to achieve. Therefore, along with the benefit of a non-invasive alternative, a
more accurate biosensor version could prove to be of significant value.
Traditional biosensors are limited in their signal capture efficiency of a biological
recognition event. Therefore, the use of nanomaterials in biosensors has become more
popular. Due to their lower detection limits, ability to immobilize an increased quantity of
bioreceptor units at a reduced volume, and ability to act as a transduction element,
nanomaterials are very promising for use in biosensors [15].
Methods with increased sensitivity have been explored, particularly using fluorescence
resonance energy transfer (FRET). However, such methods require the use of an external
energy source which is difficult to implement within a biological environment [16].
Therefore, bioluminescence resonance energy transfer (BRET) has been explored as an
alternative that does not require an external energy source and are therefore not limited in
their applicability in biological settings [17–19].

1.2 Resonance energy transfer
Bioluminescence resonance energy transfer-based sensors offer a high degree of sensitivity
and reliability in a procedure that is both easy to perform and relatively inexpensive. BRET
sensors utilize bioluminescence generated from a luciferase enzyme found in the sea pansy
in order to donate energy to a fluorescence molecule that will emit a measurable quantity
of fluorescence [17–19]. This system can be used to monitor an easily detectable light
signal in real time with a high degree of sensitivity. BRET sensors are a less invasive and
easier to perform modification of fluorescence resonance energy transfer which requires
an external light source to initiate the fluorescence transfer [16]. No longer requiring an
external light source has made BRET attractive for use in biological systems. Limitations
of

a

fluorescence-based

sensor

include
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tissue autofluorescence and photobleaching. Background emission from tissue, otherwise
known as autofluorescence, was found to be a limiting factor in the sensitivity of reporters
[20–22]. Research has reported significantly higher autofluorescence levels in fluorescent
reporters

when

compared

to

bioluminescent

reporters

[21,23]. Chemiluminescent resonance energy transfer (CRET) is a related technique that
relies on the oxidization of a chemiluminescent compound which will excite an
acceptor fluorophore [24,25]. There are a limited number of studies done using CRET,
therefore its efficacy and biocompatibility have not been adequately proven [26,27]. Thus,
the use of bioluminescent reporters has become increasingly attractive in biological
applications.
BRET is a natural phenomenon involving the non-radiative energy transfer between a
bioluminescent donor molecule and a fluorescent acceptor molecule. When the
bioluminescent

donor,

typically

an

oxidative

luciferase

enzyme,

emits

bioluminescent energy, this excites the fluorescent acceptor and increases its emission
[22,28]. This is referred to as resonance energy transfer and only occurs when the two
proteins are within 10nm (Figure 1.1) [23]. The changes in ratio of the acceptor to donor
emissions

are

monitored

which

are

useful

in

studying

protein-protein

interactions (PPI) since the mechanism depends on distance [16,22].

Figure 1.1: Schematic of a NanoLuc (NLuc) based BRET (BRETn) design. Nluc is
the donor fluorophore and Venus is the acceptor fluorophore. Nluc and Venus are
fused to their respective proteins of interest (X and Y). BRET signal is
detected when the proteins are in close proximity. Reprinted by permission from
Springer Nature [23]. Copyright 2016.
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FRET and, by extension, BRET, is a distance dependent mechanism. The efficiency of the
energy transfer (E) is defined as the quantum yield of the energy transfer transition [29].
The efficiency depends on the distance between the donor and acceptor, usually up to 10
nm. In addition, the emission spectrum of the donor should overlap with the acceptor’s
absorption spectrum. The donor emission dipole moment and the acceptor absorption
dipole moment should be relatively oriented [30,31]. The efficiency is calculated using
equation (1.1):
𝑅6

0
𝐸 = 𝑅6 +𝑟
6

(1.1)

0

Where r is the distance between the donor and acceptor and R0 is the Förster distance of
the donor acceptor pair which is the distance where E = 50%.
The Förster distance is given by equation (1.2):
1

𝑅0 = 0.21[𝜅 2 𝑄𝐷 𝑛−4 𝐽(𝜆)]6

(1.2)

Where J(λ) is the spectral overlap between donor emission and acceptor absorption, QD is
the quantum yield of the donor, n is the refractive index of the medium, and κ2 is an
orientation factor related to the relative orientation of the donor emission and acceptor
absorption dipole moments.
Many limitations must be taken into consideration when constructing a BRET sensor
system. Conventional BRET systems utilize bioluminescence proteins as donor molecules
and organic dyes as acceptor molecules. However, suitable BRET pairs utilizing organic
dyes are often limited due to narrow emission wavelengths of the dyes [22]. In order to
increase the flexibility of the acceptor molecule, quantum dots have been incorporated in
the place of organic dyes. Quantum dots offer a wealth of advantages, in particular, a
tunable emission wavelength. Therefore, the challenges of constructing a BRET sensor
system can be overcome using inorganic nanomaterial as acceptor molecules.
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1.3 Bioluminescent proteins
There exists a variety of bioluminescence donors, many of which are derived from
naturally occurring enzymes in animals such as the firefly or the sea pansy. Among the
different donors, each has clear advantages and disadvantages in certain applications.
Therefore, certain donors are considered for certain tasks according to their properties.
Commonly used bioluminescence donors include the luciferases, a class of oxidative
enzymes, which catalyze the oxidative decarboxylation of luciferin. Luciferins are lightemitting compounds that generate bioluminescence upon undergoing oxidation, which
results in the emitting of light upon decaying from an excited state to its ground state. Upon
oxidation of the luciferin in the presence of oxygen, carbon dioxide, oxyluciferin (III) and
light are released [32].

1.4 Quantum dots
Quantum dots (QD) are light-emitting semiconductor nanocrystals with optical and
electrical properties. Applications for QDs range from bioanalytical assays, live cell
imaging, fixed cell and tissue labeling, biosensors and in vivo animal imaging [33]. The
fluorescence properties of QDs are determined by the core materials and the shell layer,
which removes surface defects and prevents nonradiative decay [34]. The optical property
of QD is a result of the quantum confinement effect of semiconductor materials. The
quantum confinement effect refers to the size and composition dependent properties of the
semiconductor gap energy. Nanocrystals smaller than the Bohr excitation radius have
quantized energy levels which depend directly on the size of the nanoparticle. This allows
the development of fluorescence emitters with precisely tuned emission wavelengths. For
example, cadmium selenide (CdSe) has a bandgap of 1.7 eV (corresponding to 730nm light
emissions). Through the altering of the nanocrystal diameter from 2 to 7nm, the QD can be
tuned to emit between 450 to 650nm. Altering the composition of the core material can
also change the emission wavelength. Thus, QDs have the benefit of being tuned to produce
a vast array of fluorophores with the same material [35].
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Typically, BRET sensors utilize fluorescent proteins [19,20,36–38] or organic dyes
[39,40] as acceptors. However, recent studies report the use of nanoparticles such as
quantum dots (QD) to be effective. QDs have the advantage of adjustable
emission depending on size, superior brightness, high photostability, and multiplexing
[41,42]. Fluorescent semiconductor quantum dots were previously limited in their
application for in vivo imaging due to requiring excitation from an external source of light
[20–23]. QDs can be excited by a broad range of wavelengths, from UV to the visible
region. Therefore, they are able to be excited by virtually all bioluminescent proteins that
are currently being used in BRET sensors [22]. In addition, their emission
spectra are particularly narrow and tunable by size, thereby demonstrating excellent
separation from the emission peak of bioluminescent proteins. QDs are also characterized
by superior brightness and photostability, which are ideal traits for use as BRET acceptor
molecules. QDs are also exceptionally resistant to photo and chemical degradation, feature
large effective Stokes shifts, and boast high molar extinction coefficients that exceed
organic dyes by 10-50 times [32]. Due to a high molar extinction coefficient, QDs can
absorb 10-50 times more photons than organic dyes at the same excitation photon flux [43].
QDs are significantly more resistant to photobleaching, therefore, they are well-suited for
continuous tracking studies over a long period of time [44]. Due to having a longer excited
state lifetime, QDs will continue to emit light for long enough that background
autofluorescence emission is over before QD emission ends [44]. The large Stokes shifts
(measure of distance between excitation and emission peaks) of QDs can be used to
improve detection sensitivity. Organic dyes with small Stokes shift are buried by strong
tissue autofluorescence, whereas QD signals with large Stokes shift are easily detected
above the background [42]. Tunable emission spectra are highly desirable for tracking
multiple parameters such as in multiplexing. QDs are attractive in this regard because their
broad absorption profiles allow simultaneous excitation of multiple colors [42].
Although not normally biocompatible, QDs can be modified through surface
functionalization with hydrophilic ligands such as thiols, amine or carboxyls [45]. In
addition to mediating solubility of the QDs, the ligands serve as a point of chemical
attachment for biomolecules. For BRET sensors, these ligands can be utilized to conjugate
the QDs to bioluminescent proteins or any such proteins [46].
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When compared to organic dyes, multiple QDs are able to interact with a single BRET
donor molecule. For example, for a single donor-dye acceptor pair, the FRET efficiency
would be 22%. Increasing the number of acceptors to five increases the efficiency to 58%
[32].
Cadmium telluride (CdTe) are well established and high-quality quantum dots which
consists of II/VI semiconductors. The ability to synthesize CdTe with different capping
ligands or encapsulated give them great potential for biological probes and optoelectronic
devices [47]. Through the aqueous solution preparation method, QDs can be synthesized
to be more biocompatible in addition to improved water stability [48,49].

1.5 Hypothesis
Bioluminescence resonance energy transfer is an ideal method for the detection and
measuring of low concentration analytes such as glucose in tears. The challenge in the
traditional BRET sensor design requires very narrow and specific BRET pairs. We
propose the construction of a BRET-based biosensor using a BRET pair that is very
flexible. In this novel BRET construct, the traditionally used BRET acceptor has been
replaced with quantum dots. Cadmium tellurite quantum dots with an emission
wavelength of 580nm will be conjugated to a glucose binding protein which is already
conjugated to Renilla luciferase. Renilla luciferase will emit at 480nm in order to excite
the quantum dots. The glucose binding protein will change conformation upon binding
glucose and will bring the BRET pair closer together, thereby increasing the emission of
the quantum dots.

1.6 Thesis objectives and motivation
Bioluminescence resonance energy transfer sensors offer a high degree of sensitivity and
reliability in a procedure that is both easy to perform and relatively expensive. BRET
sensors are more biocompatible and easier to perform modification of fluorescence
resonance energy transfer which requires an external light source to initiate the
fluorescence transfer. No longer requiring an external light source has made BRET
attractive

for

use

in

biological

systems,

which

may

be

susceptible
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to tissue autofluorescence and photobleaching. Recent works have explored the potential
of measuring other bodily fluids, which have a strong correlation to blood glucose levels.
BRET sensors utilizing a nanomaterial-based acceptor such as quantum dots have only
been recently explored. Therefore, the motivation of this thesis is to explore the potential
of a bioluminescent protein and quantum dot pair for use in a BRET sensor. In this study,
the interaction between the two and how they can be effectively implemented into a BRET
system will be investigated.
The objective of this thesis is to integrate inorganic nanomaterial and bioluminescence
proteins into a non-invasive means of measuring blood glucose. The intent is to construct
a BRET sensor utilizing quantum dots as the donor molecules and bioluminescent enzymes
as the acceptor molecules and evaluate their performance in vitro. The proposed senor will
use the luciferase from Renilla reniformis (emission wavelength λcm = 480nm) and
incorporate it into a recombinant protein with glucose binding protein (GBP). The
recombinant protein will be conjugated to CdTe quantum dots (emission wavelength λcm =
565nm).
The GBP acts as a separator of the donor and acceptor, keeping them at a distance from
each other. Due to the distance dependent relationship of the donor-acceptor pair, the
BRET emission will be weak [50]. However, when GBP binds glucose, it will change
conformation, thereby shortening the distance between the donor-acceptor pair and
increasing the BRET emission (Figure 1.2).
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Figure 1.2: Schematic of the proposed BRET sensor. Quantum dots (QD) are used
as the acceptor and Renilla luciferase (Rluc) as the donor. GBP separates the donoracceptor pair and will change conformation upon binding glucose, thereby
increasing the BRET emission intensity.
This study will lay the foundation for the use of inorganic nanomaterial in BRET sensors
for the detection of small molecules relevant to human disease, particularly using quantum
dots to offer an alternative and more sensitive means of monitoring concentrations of small
molecules in the body. The following are sub-objectives in order to achieve the main
objective:


Synthesize and modify cadmium tellurite quantum dots with carboxylic groups in
order to increase hydrophilicity and biological compatibility. Modifications enable
the quantum dots to be conjugated to the protein



Construct a recombinant plasmid containing the glucose binding protein, Renilla
luciferase and His-tag protein, then transform into E. coli for rapid expansion.
Extract and purify the target protein using a His-trap column.



Bioconjugate the recombinant protein onto the CdTe



Investigate optimizations of the construction of the sensor, particularly the protein
to quantum dot ratio, the bioconjugation process, and concentration of glucose.



Evaluate the performance of the biosensor when applied to a solid substrate.
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1.7 Thesis overview
Chapter 2: Literature review
This chapter focuses on reviewing applications and techniques of biosensing, particularly
involving quantum dots. In addition, techniques for glucose biosensing will be reviewed.
Chapter 3: Experimental methods
This chapter will describe the experimental procedures for synthesizing the different
components of the biosensor. Procedures for synthesizing water-soluble cadmium tellurite
quantum dots, construction of the recombinant plasmid, extraction and purification of the
protein, conjugation of the protein and quantum dots are discussed in this section. In
addition, characterization methods are discussed, such as the sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and fluorescence emission spectra.
Chapter 4: Biosensor evaluation and optimization
The biosensor performance is evaluated. Optimization of the performance is evaluated
through investigating changes in protein to quantum dot ratio, the bioconjugation process,
and concentration of glucose present.
Chapter 5: Biosensor evaluation on solid substrate
Performance of the biosensor on a solid substrate is evaluated. The process by which the
solid substrate is synthesized and also the conjugation process of the biosensor onto the
substrate is discussed.
Chapter 6: Summary and future work
Conclusion and future of the sensor. Outlining how some aspects can be improved and its
relevance compared to current work.
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Chapter 2

2

Literature review

This chapter provides a literature review on the following aspects; (1) bioluminescence
proteins in BRET sensors; (2) BRET phenomena and design; (3) quantum dots in BRET
sensors. Different bioluminescent proteins are described based on their applicability in
BRET sensors. In addition, the foundations and parameters for defining the BRET
phenomena are described in detail. Then, BRET sensors utilizing quantum dots that have
been previously developed are highlighted.

2.1 Bioluminescence proteins
FRET and, to an extent, BRET have typically utilized fluorescent proteins for both donor
and acceptor molecules. Due to the need for external light to stimulate the fluorescent
proteins, bioluminescent proteins have become increasingly attractive for use in
resonance energy transfer-based sensors. Bioluminescent proteins do not require an
external light source, only requiring a substrate, which is oxidized to produce light.
Therefore, bioluminescent proteins have become more widespread in their use as
reporters or donor molecules for BRET systems when measuring protein-protein
interactions and small molecule concentrations[51].
There exists a variety of bioluminescence donors, many of which are derived from
naturally occurring enzymes in animals such as the firefly or the sea pansy. Among the
different donors, each has advantages and disadvantages in certain applications.
Therefore, certain donors are considered for certain tasks according to their properties.
This section aims to highlight some of the differences between bioluminescence donors
and how they can be applied in BRET constructs.
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Table 1: Summary of bioluminescent proteins
Name

Size (kDa)

Aequorin

22

Bacterial luciferase
(Lux)

Emission
(nm)

Substrate

469

Coelenterazine

α subunit: 40
β subunit: 35

490

FMNH2
long-chain aliphatic
aldehyde

Firefly luciferase (Fluc)

61

562

D-luciferin

Renilla luciferase (Rluc)

36

480

Coelenterazine

Gaussia luciferase
(Gluc)

19.9

480

Coelenterazine

Vargula luciferase
(Vluc) or
Cypridina luciferase

62

460

Vargulin (Cypridina
luciferin)

Metridia luciferase

24

480

Coelenterazine

Nano luciferase (Nluc)

19

460

Furimazine

2.1.1

Aequorin

First discovered in the jellyfish Aequorea victoria, aequorin is a 22 kDa photoprotein that
emits blue light at 469 nm upon binding its substrate, coelenterazine [52,53]. Given its high
sensitivity for calcium, aequorin is most often used to detect calcium concentration from a
single cell by expressing it using recombinant aequorin [54–56]. Typically, aequorin is
recombined with polyols to increase its stability [56]. Addition of coelenterazine to the
medium allows it to passively diffuse into the cell, and aequorin emits blue light with
intensity proportional to the calcium levels within the cell [53]. However, aequorin has a
low light quantum yield compared to other bioluminescent proteins. Furthermore, its
substrate, coelenterazine, has been shown to be unstable and have poor biodistribution [57].
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2.1.2

Bacterial Luciferase

Bacterial luciferase (Lux) consists of two subunits: alpha, which is 40 kDa, and beta, which
is 35 kDa; it emits blue light, which peaks at 490 nm [58,59]. Lux is an ATP-dependent
luciferase and requires oxygen and NADPH as cofactors, in order to work on its substrate:
long-chain aliphatic aldehydes and flavin mononucleotide (FMNH2) [58,59]. It is most
often used as a bacterial reporter, more specifically in luminous bacteria for autonomous
bioluminescence oxidation reaction [59]. The long-chain aliphatic aldehydes have shown
to be able to freely diffuse through the cell membrane and have high binding affinity for
Lux [58]. Like aequorin, Lux demonstrates poor light quantum yield as well as poor
thermostability [60]. Furthermore, studies are limited to luminous bacteria due to the
cytotoxicity of aldehydes [61].

2.1.3

Firefly Luciferase

Firefly luciferase (Fluc), the first luciferase to be discovered, is a 61 kDa protein that emits
blue light at 562 nm when exposed to its substrate, D-luciferin [62–64]. Similar to Lux,
Fluc is ATP-dependent and requires the presence of co-factors, oxygen and magnesium, in
order to complete its reaction with D-luciferin [63–65]. Since its discovery, Fluc has been
used in various fields as a biosensor through recombination with another protein of interest
and as ATP sensor, taking advantage of its ATP-dependency [66–68]. Fluc demonstrates
high light quantum yield making it superior in comparison to Lux and aequorin [64].
Nonetheless, disadvantages involving Fluc as well as D-luciferin has emerged. Although
D-luciferin had been presumed to have good biodistribution given its ability to cross the
blood-brain barrier and blood-placental barrier, recent studies have discovered its low
tissue permeability, which results in heterogenous biodistribution [57,69,70]. Furthermore,
D-luciferin has low affinity for Fluc, which may result in false negative signals [57].
Moreover, Fluc and D-luciferin only gives a single imaging signal limiting studies to a
single molecular event or a single population of cells [57]. Finally, the large size of Fluc
may lead to steric hindrance when used as a recombinant protein [65].
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2.1.4

Renilla Luciferase

Renilla luciferase (Rluc), first discovered in sea pansy, Renilla reniformis, is a 36 kDa
protein that emits blue light at 480 nm when worked with its substrate, coelenterazine [71–
73]. Rluc is often used as a marker for gene expression in mammalian cells and as a
biosensor when recombined with a protein of interest [72,74]. As it originates from nonmammalian cells, the gene sequence for Rluc includes codons that are uncommon in
mammalian cells, which limits Rluc expression in the cells [71]. Furthermore, Rluc has
shown to have low enzymatic turnover and quantum yield when compared to Fluc [73,75].
In addition, the problem of instability and poor biodistribution of coelenterazine remains
[57].

2.1.5

Gaussia Luciferase

Gaussia luciferase (Gluc) is similar to Rluc due to having an emission peak at 480 nm,
ATP-independence, and bind the same substrate, coelenterazine [65,73,75]. Gluc is smaller
than Rluc at 19.9 kDa and originates from Gaussia princeps, thus eliminating the problem
of uncommon codons [75]. Gluc has been used as a bioluminescent label for in vitro
hybridization assay as well as a biosensor through recombination with another protein of
interest [65,76]. Gluc is naturally secreted by the cells, which allows for it to be detectable
in cell medium [75,77]. It has also been characterized to be more sensitive compared to
Fluc and Rluc [77]. Despite its sensitivity, quantum yield remains low and is accompanied
by problems involving coelenterazine [57,73,78].

2.1.6

Vargula Luciferase

Vargula luciferase (Vluc), also known as Cypridina luciferase, is a 62 kDa protein that
emits blue light at 460 nm when worked with its substrate, vargulin, also known as
cypridina luciferin [79–81]. Similar to Rluc, Vluc has been used as a marker for gene
expression in mammalian cells as well as a biosensor when recombined with another
protein of interest [80,82]. Also, similar to Gluc, Vluc is also naturally secreted by cells,
and it is detectable in cell medium [82]. One advantage of Vluc over other luciferases is its
glow-type bioluminescence compared to flash-type exhibited by other luciferases [81].
Previously, Vluc has been shown to be difficult to express and purify from bacterial
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systems; however, the issue has been successfully addressed by using a truncated derivative
of Vluc, which shows higher degree of expression and purification while retaining its
enzymatic activity [81].

2.1.7

Metridia Luciferase

Like Rluc and Gluc, Metridia luciferase also emits blue light at 480 nm, is ATPindependent, and works on the same substrate, coelenterazine [73,76,83]. Smaller than
Gluc but bigger than Rluc, Metridia luciferase is 24 kDa protein [83]. Similar to all
luciferase, Metridia luciferase has been used as a biosensor by recombining it with another
protein of interest [83]. Metridia luciferase is also naturally secreted by cells similar to
Vluc and Gluc [76]. In addition, its low molecular mass serves as an advantage in
recombination [83]. However, Metridia luciferase demonstrates low quantum yield, and
the disadvantages of coelenterazine discussed before stays relevant [57,73].

2.1.8

Nano Luciferase

Nano Luciferase (Nluc) is a recently developed luciferase that uses furimazine as a
substrate to emit blue light at 460 nm [84–86]. It is the one of the smallest luciferases to be
characterized at 19 kDa and has the one of the brightest bioluminescence to date [84,86].
Not many studies using Nluc has been published compared to other bioluminescent
proteins as the molecule is fairly new; the published studies typically use Nluc as a
biosensor through recombination with their protein of interest [86,87]. Nluc exhibits glow
type bioluminescence, similar to Vluc, with long half-life of approximately 2 hours [84,86].
Furthermore, furimazine has shown to exhibit lower background noise when compared to
coelenterazine.

2.2 BRET phenomena/design
Originally observed in marine animals, such as the sea pansy Renilla reniformis, BRET is
a nonradiative energy transfer from a bioluminescent donor to a fluorescent acceptor.
While the acceptor has traditionally employed the use of yellow fluorescent protein (YFP)
when paired with Rluc, recent research has investigated the use of quantum dots as a
suitable replacement for YFP [22,42,44,47,89–92]. When the donor is in close proximity
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to the acceptor, the energy that results from catalytic degradation of a substrate, such as
CTZ, is transferred from the donor to the acceptor, therefore inducing two light emissions.
One light emission at 480nm corresponds to the donor and in the case of YFP, the second
emission at 530nm corresponds to the acceptor. Therefore, the presence of both emissions
indicates the coexpression of the donor and acceptor in close proximity [93].
The transfer of energy from donor to acceptor is only able to take place within 1-10nm
which is also the distance for protein-protein interactions in the physiological environment.
Therefore, observing a BRET signal indicates that in a system placed to monitor proteinprotein interactions, such an interaction has occurred [94]. The design of the BRET partners
should meet the following requirements: (1) the distance between the donor-acceptor pair
should be less than 10 nm; (2) there should be spectral overlap between the donor emission
and the acceptor excitation wavelengths; (3) the dipoles of the donor and acceptor should
be aligned in order to maximize transfer of resonance energy through nonradiative dipoledipole coupling; and (4) higher donor quantum output results in increased energy transfer
to the acceptor therefore the donor quantum output should be greater than the energy loss
due to decay [94–97].
Photoluminescent QDs are rapidly becoming popular choices for use in biomedical
applications such as labeling, bioimaging, and biosensing. QDs are particularly appealing
due to their high photostability, continuous absorption spectra, and size-dependent
fluorescence [98–102]. QDs are typically synthesized as hydrophobic and therefore
require a number of modifications in order to be suitable in biological environments.
Modifying QDs to be suitable for solubility in water results in a decreased quantum yield
and therefore requires surface modifications [88,103]. There exist three strategies to
make QDs water soluble: ligand exchange, silanization, and encapsulation.
In ligand exchange, the original hydrophobic coating is replaced by a water-soluble
bifunctional molecule. Once attached to the QD surface, a hydrophilic tail makes the QDs
able to bioconjugate, usually with other surface groups such as thiol, amine and carboxyl
[104].
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Silanization is an extension of ligand exchange where the QD is coated in a silica shell,
which is non-toxic, chemically inert and optically transparent. The silica shell protects the
QD from oxidization and provides a matrix, which enhances stability in the environment.
The silica is biocompatible and can be functionalized for bioconjugation [105–107].
Encapsulation utilizes different carriers such as amphiphilic polymers, polymeric
microbeads, and liposomes [108–110]. These coating molecules have hydrophobic and
hydrophilic units, therefore can interact strongly with the QD surface and the aqueous
outside environment [108]. Liposomes are particularly popular due to their porous
spherical structure and high loading capacity [109,111]. However, they are limited due to
susceptibility to temperature and pH changes [112].
There are two primary approaches to bind biomolecules onto the surface of QDs. Noncovalent which is mediated by interactions between the biomolecules and the QD surface,
and covalent linking which is achieved through chemical reactions of molecular surface
groups [110,113].
Non-covalent binding is achieved through two types of interactions; electrostatic
interaction between oppositely charged molecules and high affinity secondary
interactions. QDs are negatively charged on the surface, therefore can be electrostatically
coupled to positively charged proteins [110,114]. High affinity secondary interactions are
interactions between functional groups on the surface of the QD and the biomolecule.
Biotin-avidin is a commonly utilized combination, though limited by the increased size of
the product [114,115]. The interaction between His-tagged biomolecules and Ni-NTA is
widely used in bioconjugation and often used for developing a QD probe for performing
Western blot analyses [114,115].
Covalent binding involves the reaction between functional groups on QDs and
biomolecules. Crosslinkers can be used to bind the molecules. Zero-length crosslinkers
such as 1-ethyl-3-(3-dimethylami-nopropyl) carbodiimide (EDC) are used because they
will not add any more atoms [116]. Carboxylic functionalized QDs are among the most
popular due to the abundance of free amine groups on proteins, which they can conjugate
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with [117]. The most popular method utilizes EDC which mediates the formation of an
amide bond between the carboxyl on QDs and amines on biomolecules [116,118].
Quantum dots cores consist of various metal complexes which have raised questions
about their application in a biological setting [119]. This concern is commonly resolved
by adding organic coatings such as methoxy-polyethylene glycol (PEG) to the surface in
order to increase biocompatibility [120]. Commonly used quantum dots include CdTe
and CdSe and all of these metals are known to be toxic to humans when exposed upon
degradation of the quantum dots [121–124]. There is lack of biocompatibility data for
quantum dots and little research done on the effect on humans. Part of the reason can be
attributed to the various factors related to physicochemical properties of quantum dots
like size, charge, concentration, outer coating and mechanical stability [125,126]. Various
studies have found adverse effects due to quantum dots [127] and some have found little
to no adverse effects, given some modifications [128,129]. Studies have determined that
quantum dots have a significantly long half-life and the degradation of fluorescent
particles taking almost 12 weeks in the liver [120,130]. This uncertainty in terms of
biocompatibility warrants further investigation, particularly in human subjects.

2.3 Quantum dots in BRET sensors
Quantum dots have been reported for their distinct advantages when used as acceptors in
BRET sensors. Quantum dots have the distinct advantage of an adjustable emission based
on their size, which can be controlled during their synthesis. In one particular study, the
emission of the quantum dots could be adjusted by adjusting the feeding ratio of
indium/zinc [46]. By increasing the amount of indium compared to zinc, the emission
wavelength could be increased (Figure 2.1). The quantum dot emission can also be
adjusted by varying the refluxing period during synthesis. Tunable emissions are
particularly attractive for BRET sensors because the flexibility of the quantum dots
allows them to be paired with a variety of bioluminescent proteins. Different types of
bioluminescent proteins have varying emission wavelengths; therefore, it is advantageous
for quantum dots to adjust their emissions in order to align with the protein emission.
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QDs have been used with a variety of donor molecules such as Rluc [22,131,132], Fluc
[51,133], and Nluc [134] for developing biosensors and biomarker assays in addition to
in vitro and in vivo imaging [132].

Figure 2.1: Photoluminescence spectra under irradiation of a UV lamp (12 W,
365nm) of Ag:ZnInSe QDs at different In/Zn feeding ratios 0-50% from left to right.
All samples are left to react for 4h. Reprinted (adapted) with permission from [46].
Copyright 2000 American Chemical Society.

2.3.1 Quantum dot-based BRET sensors for detecting biomolecules
Carboxylated quantum dots (Qd-625) were conjugated to a DNA probe (Qd-D-P) while
oligonucleotide probes were conjugated to Rluc (Rluc-P). The sensing scheme uses the
two antisense oligonucleotide sequences which will anneal adjacent to each other in a headto-head fashion when the target is present (Figure 2.2) The maximum BRET signal was
obtained by optimizing the spacing between the Rluc-P and Qd-D-P when hybridized to
the target. Optimization was done using oligonucleotide targets, which create various
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separation distances. The optimal separation distance was found to be 15 nucleotides.
Hybridization time between labeled probes and target was studied and found the optimal
time to be 5 and 35 minutes. In conclusion, an on-type, BRET-based sensing platform
incorporating Rluc and QD with a 5-minute detection time of a nucleic acid target in
vitro was developed. The method was also determined to be highly sensitive (detection
limit of 0.54 pmol) and selective against mismatch targets [135].

Figure 2.2: Schematic of BRET based on-type sensing system. The Rluc-P and QdD-P hybridized to the target in head-to-head fashion permitting BRET between
Rluc and Qd. Reprinted from [135], with permission from Elsevier
Near-infrared region optical detection of apoptotic cells was achieved using BRETcoupled annexin V-functionalized
with Rluc and annexin V was

quantum

dots.

A

conjugated to

recombinant

protein
glutathione

coated CdSeTe/CdS QDs (Figure 2.3A). Annexin V recognizes phosphatidylserine (PS)
on the outer monolayer of the membrane of apoptotic cells and binds to it in the presence
of Ca2+ ions (Figure 2.3B). The QDs act as a probe for detecting apoptotic cells with a peak
emission at 830 nm and a high quantum yield of 61% in aqueous solution. This method
was presented as a simple, rapid, and efficient method for synthesizing a BRET-induced
NIR emission probe and with its low phototoxicity could prove to be useful in highly
sensitive detection of apoptotic cells in vivo and in vitro [136].
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Figure 2.3: A) Synthetic method for the preparation of recombinant protein
(HisRLuc-annexin V)-conjugated QDs (annexin V-Rluc-QDs). B) Schematic
representation for the binding of annexin V-RLuc-QDs to PS on plasma membrane
of apoptotic cells in the presence of Ca2+ ions. Reprinted with permission from
[136]. Copyright 2017 John Wiley and Sons
A general BRET homogenous immunoassay was developed for the determination of small
molecules. This assay is based on QDs and Rluc which produce variable energy transfer in
the presence of different concentrations of free fluoroquinolones (FQs). In the absence of
free FQs, QDs conjugated to norfloxacin (QD-NOR) are recognized by a single-chain
variable fragment (scFv), which is conjugated to Rluc, and are able to produce an energy
transfer (Figure 2.4A). Otherwise, the presence of Free FQs prevents the Rluc and QDs
from producing and energy transfer (Figure 2.4B). Similar results for cross-reactivity to
seven

representative

FQs were

found when

compared

to

an

enzyme-
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linked immunosorbent assay (ELISA). The LOD of the QD-BRET immunoassay was
2.54 ng/L with a linear range which covers 4 orders of magnitude (0.023 to 25.60 ng/ml).
The use of QDs enables the flexibility of more choices for donor substrates given the wider
excitation range of the QDs. The authors noted that by replacing the target of interest,
the immunosensor could be used with a variety of other small molecules and could open
up the possibility of multiplex detection using different QDs [92].

Figure 2.4: A) In the absence of free FQs, QD-NOR is recognized by scFv-Rluc and
the Rluc and QDs are in close proximity; energy is released from the substrate and
transferred to the QDs via BRET. B) In the presence of free FQs, the scFv-Rluc
binds to the free FQs and the distance between the Rluc and QDs is too far to
realize energy transfer. Reprinted (adapted) with permission from [126].
Copyright 2016 American Chemical Society.
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In

one

particular

study, CdSe/ZnS core-shell

quantum

dots

(QD705) were

conjugated to Nluc (Figure 2.5). This construct was used to image tumors by conjugating
it to cyclic arginine-glycine-aspartic acid (cRGD) peptides, which were selected due to
having strong affinity for integrin αvβ3 , which are known to be expressed on various tumor
types. When intradermally injected into the hind paw of a mouse, the popliteal lymph
nodes could be visualized by bioluminescence at 5 minutes post injection (p.i.) without any
background signal. To demonstrate tumor-targeting capabilities, the sensor was injected
into mice with integrin expressing U87MG human glioblastoma cell tumors. After
2 hours, p.i. organs were harvested and ex vivo imaging found a noticeably visible signal
in the tumors injected with QD-Nluc-cRGD. When compared to traditional fluorescence
techniques, bioluminescence demonstrated higher sensitivity due to the distance dependent
relationship of BRET components. Using the BRET conjugate, the tumor to background
ratio was exceptionally high (>85) [134].

Figure 2.5: QD-Nluc-cRGD conjugate. Chemical communications by Royal Soceity of
Chemistry (Great Britain). Reproduced with permission of ROYAL SOCIETY OF
CHEMISTRY.

2.3.2 QD-based BRET sensor used in bioimaging in vivo
BRET-QD nanoparticles were applied to in vivo lymphatic imaging in mice. QD655
covalently

linked

to

Luc8 protein, an

eight-mutation

variant

of Rluc, were intracutaneously injected into 10 weak old normal athymic female mice at
different sites, the chin, ear and paws. After 5 minutes, the imaging was carried out (Figure
2.6). Using BRET-QD655 has the advantage over traditional bioluminescence imaging
(BLI) in that NIR light emission is more favorable in tissue penetration. All lymph nodes
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were visualized when injected with BRET-QD655 constructs and since there is no
excitation light, the BRET signal more accurately represents the concentration of the
quantum dots in the lymph nodes, leading to better quantitative imaging [137].

Figure 2.6: BRET lymphatic images of different lymphatic basins. BRET-QD655
were injected at all four paws (a), the ear and forepaw (b), the chin (c), or five
different sites (d: both forepaws, both ears and chin). Copyright 2011 John Wiley
and Sons
The use of QD nanoparticles as a tool for non-invasive investigation of mammalian
spermatozoa was explored. CdSe/ZnS QD nanoparticles with emission wavelengths of 655
nm were conjugated to nona-Arginine R9 peptide, which facilitates cellular internalization.
The QDs were linked to RLuc and used to label boar spermatozoa and were assessed for
changes in sperm motility, viability, and fertilizing potential. In vitro assays concluded no
adverse effect of the BRET-QD on the spermatozoa. The results suggest the strong
potential for a novel imaging technique for tracking BRET-QD labeled spermatozoa to
better understand sperm migration within the female genital tract [138].
BRET coupled near infrared quantum dots were used as a highly sensitive near-infrared
optical detector of epidermal growth factor receptors expressed on cancer cells. His-tagged
Rluc recombinant protein (HisRluc·GB1) were conjugated to glutathione-coated
CdSeTe/CdS QDs (GSH-QDs) to form conjugated QDs (GB1·Rluc-QDs). The
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recombinant protein consists of a luciferase enzyme and immunoglobulin-binding domain
(GB1) of protein G. The GB1 domain allows the GB1·Rluc-QDs to bind the Fc moiety of
immunoglobulin G which is then used as a molecular imaging probe using NIR
fluorescence and BRET-coupled NIR emission. In order to detect EGFRs on cancer cells,
anti-EGFR monoclonal antibodies were conjugated to the GB1·Rluc-QDs (Figure 2.7).
The detection sensitivity of EDGRs by BRET-coupled NIR emission of the GB1·RlucQDs was found to be over three times higher than NIR fluorescence of the QDs. Therefore
the conjugation of the antibody with GB1·Rluc-QDs have proven successful in performing
BRET-based highly sensitive NIR imaging of EGDRs in living cells [91].

Figure 2.7. Prepared BRET-coupled NIR-QDs (GB1·Rluc-QDs) using glutathionecapped QDs (GSH-QD). BRET-coupled NIR emission from antibody conjugates
with GB1·Rluc-QDs occurs in the presence of coelenterazine (CTZ). Reprinted
(adapted) with permission from [129]. Copyright 2018 American Chemical Society.
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Chapter 3

3

Experimental methods

3.1 Recombinant plasmid construction
The recombinant plasmid was constructed using the mglb gene from E. coli k-12 connected
by a six amino acid linker to the Rluc gene cloned from the plasmid pRL-null (Promega,
Inc). These encode for wild-type glucose binding protein (GBP) and Renilla luciferase,
respectively.

Primers

for

GBP

were

designed

for

cloning

(forward

5’

TATACATATGAATAAGAAGGTGTTAACCCTGTCTGC

3’;

reverse

5’

GCTGGATCCTTTCTTGCTGAATTCAGCCAGGTTG

These

primers

were

3’).

introduced at the restriction site Nde I and BamH I, respectively. A six amino acid linker
SGGGGS was inserted after the BamH I site in order to separate the GBP and Rluc. The
primers

for

Rluc

are

also

follows:

(forward

5’

AAAGGATCCAGCGGTGGTGGTGGTAGCATGACTTCGAAAGTTTATGATCCAG
3’; reverse 5’ TGTGCTCGAGTTGTTCATTTTT GAGAACTCGCTC 3’). The reverse
primer for Rluc was introduced at the restriction site Xho I. Therefore, the GBP gene is
located upstream of the fusion protein.
The PCR products were digested with their related restriction enzyme and the plasmid
pET32a (Novagen, Inc) was used to clone and express the recombinant gene. The digested
DNA inserts were ligated into the related MCS (multiple cloning site) in pET32a. A sixhistidine tail was added to the GBP-Rluc recombinant protein for use in purifying the
protein. The pET32a-GBP-Rluc plasmid was transformed into E. coli BL21 cells for rapid
expansion. The DNA sequence of the recombinant plasmid was confirmed by DNA
sequencing (Robarts Research Institute, Western University).

3.2 Recombinant protein extraction and purification
3.2.1 Bacterial culture
The bacteria were cultured on an agar plate until colonies were visible. A 5 mL starter
culture of Luria-Betrani (LB) broth containing 100 µg/mL ampicillin was inoculated with
the bacteria and grown overnight at 37°C. The culture was then used to inoculate 800 mL
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of LB broth containing 100 µg/mL and left to grow at 37°C. When the culture achieved an
OD600 of 0.375, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the culture
to a final concentration of 1mM in order to induce expression of GBP-Rluc. The culture
was then left to grow for four hours at 21°C on a shaker at 200RPM.

3.2.2 Protein extraction and purification
The bacteria culture was centrifuged at 9 000 RPM for 5 minutes at 4°C. The supernatant
was discarded and the pellet was suspended in binding solution, which is comprised of
20mM Tris/HCl, 500mM NaCl, 5mM imidazole at pH 7.4. The solution was then sonicated
on ice using 15-second bursts followed by 30 seconds of rest for 30 cycles using a Mandel
Scientific Q500 sonicator.
The solution was then centrifuged at 8 000 RPM at 4°C for 30 minutes. The supernatant
was collected and filtered using a cellulose acetate membrane syringe filter (VWR, Inc.)
with a pore size of 0.45µm.
The protein solution was purified using His-trap HP columns (GE Lifesciences. Inc.) by a
syringe pump. The column is equilibrated using binding solution and the supernatant is
loaded into the column at a rate of 0.3mL/min. The column is washed with 10 column
volumes of binding solution afterwards. In order to elute the protein from the column, and
increasing gradient of imidazole is used to wash out the column. The concentrations of
imidazole used are as follows: 40mM, 60mM, 80mM, and 120mM. Each concentration of
imidazole is used at 10 column volumes at a rate of 0.5mL/min to wash the column starting
from the lowest concentration. The imidazole used to wash out the column were then
collected in order to be used to identify the concentration in which the protein was eluted.
The gradient of concentrations was run in sodium dodecyl sulfate polyacrylamide gel
electrophoresis (10% SDS-PAGE) in order to verify that the target protein was purified
and the relative concentration in each solution. Samples were prepared in 1:1 solution with
SDS running buffer and boiled for 5 minutes. The samples were run alongside PageRulerTM
Prestained Protein Ladder (ThermoFischer Scientific). The gel was run at 120V for 34
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minutes, then stained using Coomassie Blue for 40 minutes. Destaining took place
overnight using distilled water.
Upon verification of the presence of purified protein in each of the imidazole samples, the
solutions were concentrated using an Amicon Ultra centrifugal filter (ultra-15, MWCO
10kDa, Millipore Inc.) and collected in one tube. The concentration of the protein was
determined by bicinchoninic acid assay (BCA) using bovine serum albumin as the
standard. The concentration was then adjusted to the desired amount by either centrifuging
to a lower volume or increasing the volume.

3.3 Cadmium tellurite quantum dot synthesis
Cadmium tellurite quantum dots (CdTe QDs) were prepared using a one-pot synthesis
method [139]. In a three-necked flask, 0.4mmol Cd(CH3COO)2·2H2O was dissolved in 60
mL of deionized water. After 10 minutes, 36µL TGA was added into the solution and
stirred for 5 minutes. Then 0.08mmol Na2TeO3 was dissolved in 50mL of deionized water
and added to the above solution. After 3 minutes of stirring, 160 mg of NaBH4 was added
to the solution and the pH was adjusted to 11 using 1M NaOH. The solution was refluxed
at 100°C with a condenser under open-air conditions. The desired photoluminescent
emission spectra was acquired by controlling the reaction time. In order to achieve the
spectra required for this particular project, the reaction was ended at 2 hours. The quantum
dots were then washed twice with ethanol and dissolved in deionized water.

3.4 Protein and quantum dot bioconjugation
Bioconjugation was mediated by 1-ethyl-3-(3-dimethylami-nopropyl) carbodiimide
(EDC). Varying ratios of the TGA stabilized CdTe, EDC and protein were used in order to
determine the most ideal amounts of each. The total reaction time was also varied. The
baseline ratios used are as follows: 10 µL of 2µmol/L CdTe, 10 µL of 20mmol/L EDC and
50 µL of 0.1 mmol/L recombinant protein in 80µL PBS. After the conclusion of the
reaction, Amicon Ultra centrifugal filters (MWCO 100kDa, Millipore Inc.) were used to
remove free particles from the solution.
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3.5 Solid substrate synthesis
A well-aligned zinc oxide (ZnO) nanorod array was grown on PDMS film. 0.01M zinc
acetate dehydrate was dissolved in 100 mL ethanol as a seed solution. The seed solution
was dropped on a PDMS substrate repeatedly followed by heat treatment at 100°C for 1
hour. The film was ten immersed in a mixed solution of 0.025M zinc nitrate hexahydrate
and 0.025M hexamethylenetetramine in 200 mL of distilled water. After 3 hours of heating
at 90°C, the ZnO nanorod array was grown on the PDMS (Figure 5.1) [140].

Figure 3.1: Illustration of the two-step method for fabricating nanocomposite coated
ZnO nanorod array on PDMS
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3.6 Conjugation of sensor onto substrate
CdTe QDs were conjugated to the ZnO nanoarray using EDC at a ratio of 10 000 to 1 QD.
The substrate was then washed to remove all free particles and leftover EDC. The protein
was then separately conjugated to the CdTe also using EDC at a ratio of 10 000 to 1 QD.
The sample was incubated for 1 hour, then washed of any residual particles. 5µL of 1mM
CTZ was added to the substrate and measured in the fluorescence spectrophotometer
immediately. Unless otherwise stated, all samples were incubated with 3μL of 2μM of
glucose solution for 5 minutes prior to the addition of CTZ.

3.7 Bioluminescence measurement
Measurement of the BRET signal of the biosensor was done after the sample was
incubated with 2µM of 10mM glucose for 5 minutes. Then 5µM of 1mM CTZ was added
to the sensor solution immediately before initiating the fluorescence spectrophotometer.
The spectrophotometer was set to read fluorescence intensity every 10 nm of wavelength
with a time of 0.5 seconds between each reading. Due to the concentration of protein
required, each test was repeated two or three times and the best representation was
selected to be presented.

3.8 Characterization methods
Molar concentration of the quantum dot solutions was calculated using UV-vis
spectrometry. The determination of the concentration relies on Beer’s Law using the
extinction coefficient ε (105 cm-1 M-1). For CdTe, ε = 10043 (D)2.12, where D is the
diameter of the quantum dots (nm). Using Beer’s Law, the concentration can be
calculated using equation (2):
𝜆 = 𝜀∗𝐶∗𝐿
Where C is the concentration of QDs in mol/L, and L is the path length (cm) [141].

(2)
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The concentration of the GBP-Rluc protein in solution was determined using a Micro
BCATM Protein Assay Kit (ThermoFisher Scientific). The solution concentration was
then adjusted to the desired concentration using 10mM PBS.
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4

Homogenous biosensor evaluation and optimization

4.1 Characterization
Verification of the extraction of the purified protein was completed through SDS-PAGE.
Rluc and GBP are ~36kDa and ~33kDa respectively. Taking into account the 6x His-tag
and linker, the predicted molecular weight of the recombinant protein is ~71kDa. SDSPAGE performed on the protein solution purified through the His-trap HP columns
revealed ~71kDa bands, thereby confirming the success of the purification process
(Figure 3.1).

Figure 4.1: SDS-PAGE characterization of the recombinant protein, GBP-Rluc
purified through His-trap HP columns. 1) PageRulerTM Prestained Protein Ladder.
2) Rluc only (~36kDa), 3) Unpurified protein sample, 4) Purified recombinant
protein sample (~71kDa)
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TEM imaging of the CdTe QDs determined the average particle size to be 10 ± 3nm
(Appendix, Figure 1). Photoluminescence with an excitation wavelength of 480nm
determined that the CdTe emission peak is centered at 580nm

4.2 Protein to quantum dot ratio
During the bioconjugation process, the ratio of the protein and quantum dots were varied
in order to determine the ideal ratio. The most ideal ratio will ideally allow both the
luciferase and QDs to show strong emission peaks in the emission spectra. The luciferase
emission peak would be observed near 480nm and the quantum dot emission peak would
be observed near the 580nm region. When synthesizing the quantum dots, the emission
peak was carefully set by setting the time of refluxing to 2 hours. The emission peak of the
quantum dots and luciferase were then verified individually using the fluorescence
spectrophotometer. Due to initial findings indicating the protein emission being
significantly higher than the QD, the ratio of QD was significantly increased.
GBP-Rluc purified from E. coli was conjugated to QDs synthesized using a one-pot
synthesis method. EDC was used at a molar ratio of 100 EDC to 1 QD and allowed to
conjugated for 1 hour. Results indicate a significant decrease in the intensity of the
bioluminescence emitted by the Rluc with increasing concentrations of QDs. No
discernible peak is observed for the luminescence emitted by the quantum dots despite
significant increases in the ratio of QDs to protein. This is due to the high intensity of the
bioluminescence masking the quantum dot emission. Therefore, the amount of
bioluminescent protein was reduced even further in an effort to be able to see the quantum
dot emission (Figure 4.1). In the emission spectra of decreasing protein to quantum dot
ratios, the tail end of the spectra is observed to becoming longer with a increasing ratio of
quantum dots. The presence of increased quantum dots in relation to protein demonstrates
an observable effect in the bioluminescence of the protein.
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Figure 4.2: Bioluminescence using various ratios of protein to quantum dots
from 6.25:1 to 0.0625:1.
The ratio between the protein to quantum dot was adjusted even further in an effort to be
able to observe a second peak of intensity emitted by the quantum dots. Results indicate
the peak is not observable despite drastically reducing the bioluminescence emission
(Figure 4.2). Despite no discernable peak observable in the wavelength pertaining to the
quantum dots, the bioluminescence of the protein was decreased considerably. Further
experiments used a ratio of 0.0625:1 to ensure a sufficient amount of bioluminescence but
also in the hopes of being able to observe the quantum dot peaks by adjusting other
properties of the sensor.
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Figure 4.3: Bioluminescence using various ratios of protein to quantum dots
from 0.0625:1 to 0.0156:1

4.3 EDC to quantum dot ratio
EDC to quantum dot ratio is important to maintain at a ratio, which allows for the most
efficient conjugation between the QDs and protein to occur. However, it is important to
note that too high of a ratio of EDC to QD may result in aggregation and precipitation of
the sensor components [44]. The results indicate that the ratios of EDC to QD from
10000:1, 500:1, and 250:1 result in a similar bioluminescence emission. However, using
a ratio of 100:1 resulted in significantly increased bioluminescence emission when
compared to other ratios (Figure 4.3).
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Figure 4.4: Bioluminescence for homogenous sensor samples conjugated using
varying ratios of EDC to quantum dots. Ratios range from 10 000:1 to 100:1

4.4 Conjugation time
Conjugation time is important to control due to the balance between the QD and protein
conjugation and the protein conjugating with other protein. Having an increased
conjugation time resulted in a significantly higher protein emission and a lower QD
emission. The ideal conjugation time would allow enough of the QD and protein to
conjugate, while keeping the amount of protein conjugating to each other at the minimum.
The conjugation of the homogenous sensor was tested at times of 30 minutes, 1 hour, 2
hours, 4 hours, and 6 hours. As the time of conjugation increases, the bioluminescence
emission intensity also decreases (Figure 4.4). The increase in conjugation time leads to a
increase in interactions between proteins which lead to aggregation and decreased
bioluminescence.
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Figure 4.5: Bioluminescence for homogenous sensor samples conjugated for varying
lengths of time. Time ranges from 30 minutes to 6 hours.

4.5 Evaluation of the homogenous BRET sensor with
increasing glucose concentration
In order for the sensor to be applicable in physiological conditions, the sensor should
demonstrate a quantifiable difference when there are varying concentrations of glucose
present in the medium. The performance of the sensor under varying concentration of
glucose was evaluated using a 5:16 protein to quantum dot ratio, 100:1 EDC to quantum
dot ratio and 1 hour of incubation time. Increasing the glucose concentration resulted in a
significantly lower emission of the luciferase.
Results indicate a significant decrease in bioluminescence intensity for increases in glucose
concentration (Figure 4.5). This is due to increases in BRET events as glucose
concentration increases. An increase in glucose concentration results in bioluminescence
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being absorbed by the quantum dots, thereby decreasing the measured bioluminescence
intensity.
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Figure 4.6: Bioluminescence intensity using increasing concentrations of
glucose.

4.6 Evaluation of the decay in bioluminescence in the
homogenous BRET sensor with a fixed glucose
concentration
The decay of the bioluminescence by the protein was evaluated using different
concentrations of glucose over a fixed period of time after adding the CTZ. The initial
spectrum was measured immediately after the addition of CTZ and following spectra was
measured immediately following the conclusion of the measurement of the spectrum before
it. The total time for measuring each spectrum was 10 seconds. Testing was done to
evaluate how rapidly the bioluminescence of the protein will decay for a set period of time
and whether the emission spectra of the sensor would show a discernable peak for the
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quantum dots. Results indicate significantly larger decay in bioluminescence during earlier
time intervals for all concentrations of glucose used (Figure 4.6). Considering the large
decay observed within a short period of time after adding the CTZ, all future testing should
seek to measure the fluorescence as soon as possible in order to obtain strong
bioluminescence.
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Figure 4.7: Decay of bioluminescence in 10s intervals for a protein to quantum ratio
of 0.0312:1 in glucose concentrations of (A) 2 µM, (B) 100 µM, (C) 1550 µM, (D)
3000 µM, (E) 6500 µM, and (F) 10 000 µM.
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The effect of filtering the sensor solution was evaluated, in addition to the effect of
adding glucose to the filtered solution. Results indicate a significant decrease when the
sensor solution is unfiltered or filtered through a centrifugal filter. For the solution
containing a ratio of 0.0312:1 and 0.0156:1, there exists a significant difference when
glucose is added to the filtered solution compared to the other two conditions (Figure
4.7). Without filtering the sensor solution, free GBP and potentially free QDs remain
which results in an increased bioluminescence emission. Filtering the solution for future
studies could prove to be effective in removing any bioluminescence that does not come
from the conjugated BRET sensor.
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Figure 4.8: Bioluminescence of sensor when unfiltered, filtered, and with glucose
added for ratios of (A) 0.0625:1, (B) 0.0312:1, and (C) 0.0156:1.
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The lack of a discernable peak for the QDs is not an indication that BRET did not occur.
It may be possible that the band gap of the QDs may be too large and requires too much
energy to become excited. In the future, QDs with smaller band gaps could be chosen to
increase the possibility of BRET occurring in the sensor. The intensity required from the
bioluminescence in proportion to the QD emission may be so large that the QD emission
is undetectable when compared to the tail end of the bioluminescence peak.

4.7 Conjugation of sensor onto a solid substrate
TEM imaging of CdTe QDs decorated with ZnO nanoarray (ZnO-CdTe QD) was used to
determine the diameter of the ZnO nanoarray (Figure 5.2). It was estimated to be 230 ±
10nm and the average particle size of CdTe QDs is around 10 ± 3nm (Appendix, Figure
1).

Figure 4.9: TEM micrograph of CdTe decorated with ZnO nanoarray (courtesy of
Dr. Yi Chen).
SEM micrograph of the solid sample was used to determine the length of each nanorod.
Each nanorod was estimated to be 3.0 ± 0.2μm (Figure 5.3A). The photoluminescence of
the CdTe QDs and ZnO-CdTe QD was measured using an excitation wavelength of
480nm. The maximum emission of CdTe QDs modified with thioglycolic acid (TGA) is
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centered at 617nm, while the emission of ZnO-CdTe QDs had a red shift to 620nm
(Figure 5.3B).

A

B

Figure 4.10: (A) SEM micrograph of CdTe decorated ZnO nanorod (courtesy of Yi
Chen); (B) Photoluminescence of CdTe QDs and CdTe decorated ZnO nanorods
(courtesy of Yi Chen)
Addition of 2µM of 10mM glucose then 5µM of 1mM CTZ to the solid substrate resulted
in an observable increase in photoluminescence intensity peak around 480nm. The
emission peak corresponds to the peak emission of Rluc; therefore, the protein was
successfully conjugated to the solid substrate. The quantum dot emission was not
verifiable; however, it may have been too low to detect (Figure 5.4).
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Figure 4.11: Normalized fluorescence emission of ZnO nanorod array on PDMS
film conjugated with quantum dots (CdTe) and recombinant protein (GBP-Rluc)
using EDC.

4.8 Refinement of conjugation process
Conjugation of the sensor onto the ZnO nanorod array may require different ideal
conditions such as conjugation time, EDC to QD ratio, and such. Therefore, more testing
is required to fully optimize the sensor on a solid substrate. The concentration of EDC to
be used during the conjugation of both the CdTe and the recombinant protein should be
adjusted to find the ideal ratio. The concentration of the CdTe per area of the solid substrate
should also be adjusted accordingly.
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Discussion

The results show an ideal ratio of components to be used during the conjugation process.
When comparing ratios of an increasing concentration of quantum dots compared to the
recombinant protein, the bioluminescence decreased significantly. As the ratio of
quantum dots increases, there is a larger ratio of acceptor molecules compared to donor
molecules. Therefore, more of the bioluminescence emitted by the recombinant protein is
absorbed by the quantum dots, which leads to a decrease seen in the bioluminescence
intensity found at 480nm. From these results, it is concluded that BRET is occurring
between the recombinant protein and the quantum dots, and allows us to select a ratio of
protein to quantum dots to be used in further experiments. The fluorescence readings did
not show a discernable peak from the quantum dots, however, it was concluded that the
intensity of the bioluminescence from the recombinant protein was masking the quantum
dot emission. Despite adjusting the ratio of the donor and acceptor, the quantum dot
emission could not be observed, therefore the ratio selected for further experiments was
0.0625:1. Using a ratio of 0.0625:1 ensured a sufficient amount of bioluminescence but
also was chosen in the hopes of observing the quantum dot emission when adjusting other
factors.
The ratio of EDC to quantum dots for the purposes of bioconjugation was adjusted to find
the ideal concentration of EDC to use. Using an excess amount of EDC may result in
aggregation and precipitation of the sensor components [142], therefore the ratio was
adjusted to avoid such an event. The ratio of 100:1 EDC to quantum dots was found to
have the highest intensity of bioluminescence, which was concluded to be the result of
the most efficient conjugation without the loss of bioluminescence due to protein
aggregation or precipitation.
Conjugation time was varied to determine the ideal reaction time to achieve the most
efficient bioconjugation. The conjugation time is important to control, otherwise allowing
component to react for too long may lead to aggregation and precipitation of sensor
components [142]. A conjugation time of 30 minutes yielded the highest
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bioluminescence, thereby indicating the most efficient conjugation with the least amount
of sensor component precipitation.
The integral finding was the results about the change in bioluminescence as glucose
concentration is increased. Increasing glucose concentration resulted in a decrease
bioluminescence. This indicates a BRET reaction which is evident by the decrease in
bioluminescence which can be attributed to absorption of the bioluminescence light
energy by the quantum dots. An increase in glucose concentration allows for more of the
glucose binding protein to change conformation and allow the BRET pair come into close
enough distance to initiate an energy transfer. Sensors to detect glucose, which have been
developed in the past, have utilized fluorescent proteins as acceptors or fluorescent
protein as donors instead of bioluminescent protein. In the present, there does not exist a
sensor for detecting glucose that combines the biocompatibility of light emitting enzymes
from animals and functionalized quantum dots.
The sensor, when conjugated to the ZnO nanorod array, exhibited characteristic peaks of
emission at 480nm and 565nm. These peaks indicate the successful conjugation of the
sensor onto the substrate, as well as the incidence of a BRET event. Zinc oxide has a
known emission peak at about 380nm [143], which can be observed in the
photoluminescence spectra, however the spectra does not completely capture the peak.

Chapter 6

6

Summary and future works

As the number of diabetes patients increases worldwide, the demand for a non-invasive
and accurate method for detecting glucose increases. The measurement of different body
fluids has been explored. Tear glucose in particular shows promise due to its strong
correlation with blood glucose based on previous research. Due to the low concentrations
of glucose in tears, FRET and by extension, BRET has been employed to measure these
concentrations in part due to the extremely sensitive nature of the techniques. Due to the
external energy requirement of FRET, BRET is the ideal choice due to its biocompatibility
and lack of drawbacks presented by requiring an external energy source. The combination
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of BRET and a glucose binding protein has not been extensively reported on. Therefore,
we have a developed a BRET sensor incorporating glucose binding protein and quantum
dots in order to measure low concentrations of glucose. Upon binding of the glucose
binding protein, it will change conformation, bringing a bioluminescent protein and the
quantum dots close enough to trigger BRET. Quantum dots were chosen due to having
unique optical properties and proven effectiveness in BRET constructs. They are an
excellent alternative to organic dyes and further evidence continues to build up in favor of
their advantages.
Trends regarding the bioluminescence were observed in the results. Firstly, decreasing the
ratio of protein to quantum dot resulted in decreased bioluminescence. Secondly, an
increased concentration of quantum dots has an observable, negative effect on the intensity
of the bioluminescence. Thirdly, for varying concentrations of EDC, only low ratios of
EDC to quantum dots had any observable effect on the intensity of the bioluminescence.
A ratio of 100:1 EDC to quantum dots significantly increased the bioluminescence
intensity when compared to other ratios. In addition, conjugation time had a significant
impact on the bioluminescence intensity. Increasing conjugation times resulted in
significantly lower bioluminescence intensity. Further, for increasing concentrations of
glucose added in to the homogenous sensor, bioluminescence intensity decreased.
Moreover, tests performed to measure the decay of the bioluminescence intensity over time
demonstrated that intensity decreased significantly faster at earlier time points than later
time points. Therefore, tests regarding bioluminescence intensity should be performed and
measured immediately after the addition of CTZ. Finally, filtering the sensor after the
conjugation procedure had a significant effect on the bioluminescence intensity.
Trends observed in bioluminescence indicate that the construct is particularly sensitive to
small changes in components used to synthesize the sensor. However, once the ideal ratios
of each component are found, the sensor will provide consistent results to increase its
applicability in the task of measuring blood glucose levels.
Experiments regarding the deposition of the sensor onto a ZnO nanorod array were able to
demonstrate successful deposition. Bioluminescence was observed when CTZ was added
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to the substrate, therefore it can be concluded that the protein had successfully conjugated
to the functionalized quantum dots on the surface of the ZnO nanorod array. Further testing
will be required to optimize the conjugation of the BRET pair and increase the
bioluminescence.
The development of a BRET sensor utilizing nanomaterials to detect glucose is a novel
design and has not been investigated before. This sensor construct promises to be a simple
and non-invasive method through implementation with a transducer to monitor glucose
concentrations in tears to output an accurate reading of blood glucose. This construct
utilizes quantum dots synthesized in a simple and facile process and combines them with
biocompatible proteins to detect glucose concentrations as low as
The results indicate difficulty in identifying a BRET signal as a result of energy transfer
between the protein and the quantum dots. Further findings led to the conclusion that BRET
is occurring, however the emission from the quantum dots is too low to detect when
compared to the high intensity of the Rluc bioluminescence. Futures studies should focus
on utilizing quantum dots with a smaller band gap, thereby requiring less energy from the
bioluminescence to excite. Therefore, increased quantum dot emission could potentially be
observed.
In the future, different luciferases could be implemented in place of Renilla luciferase such
as Nano luciferase, a smaller variant which has been proven to be robust and highly
sensitive. Its size has proven to a valuable asset in the bioconjugation process. In addition,
due to the non-specific nature of the bioconjugation process, other binding proteins could
potentially replace the glucose binding protein. This could lead to applications of the sensor
for detecting other small molecules besides glucose. Finally, optimizations in order to
improve the performance of the sensor in a solid substrate can be implemented. Such
optimizations may include the amount of EDC to be used for conjugated both the CdTe
and the recombinant protein, and the specific concentration of CdTe to be used per area of
the solid substrate.
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Appendices
1.

Characterization of CdTe QDs

CdTe QDs were characterized using TEM imaging by my colleague, Dr. Yi Chen, a posdoc fellow in our group (Figure 1). Photoluminescence of the CdTe QDs was observed
using an excitation wavelength of 480nm and the peak excitation was observed at 580nm
(Figure 2).

Figure 1. TEM micrograph of CdTe QDs. Average particle size is estimated to be
around 10 ± 3nm.
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Figure 2. Photoluminescence emission spectra of CdTe QDs excited by excitation
wavelength of 480nm.

2.

Initial bioluminescence testing

The photoluminescence spectra of the TGA coated CdTe QDs refluxed for 2 hours show a
strong emission peak at 580nm. These QDs were chosen in order to make sure the peaks
of the QD and the protein do not overlap but are not too far that the signal of the protein
will decay before reaching it. Increasing the reflux time shifts the emission spectra of the
quantum dots to longer wavelengths due the increasing size of the CdTe QDs, which are a
consequence of quantum confinement.
The photoluminescence spectra of the recombinant protein was found to have a large peak
centered at 480 nm. This is expected because Renilla luciferase has been well documented
to emit light within this region. The photoluminescence spectra of the recombinant protein
bioconjugated to the CdTe QDs was found have a strong peak at 480 nm, however a
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broader tail is observed in the region after 480 nm, which corresponds with the QD
emission. The quantum dot emission is not strong enough to display a peak when compared
to the luciferase emission, therefore this results in a broader tail.
Bioluminescence intensity was tested using two samples with identical ratios of GBP-Rluc
to QD, conjugation time, and EDC concentration. The only difference being that one
sample was filtered through an Amicon Ultra centrifugal filters (MWCO 100kDa,
Millipore Inc.). This was to verify the solution was indeed filtered of free particles. The
results indicate a significant decrease in bioluminescence upon filtering due to the filtering
of free GBP-Rluc and QD particles (Appendix 1)
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Figure 3: Bioluminescence intensity for two samples using identical conditions except for
one sample is filtered and the other left unfiltered.
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